Karl-Otto Sigel

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

Ludwig Kappos, Amit Bar‐Or, Bruce Cree et al. · The Lancet · 2018 · 925 citations

Medicine, Neurology, Pharmacology +9

Multiple sclerosis in Germany: data analysis of administrative prevalence and healthcare delivery in the statutory health system

Ariane Höer, G. Schiffhorst, Anne Zimmermann et al. · BMC Health Services Research · 2014 · 48 citations · Full text

Pharmacy, Health Systems, Neurology +10

Neurologist adherence to clinical practice guidelines and costs in patients with newly diagnosed and chronic epilepsy in Germany

Adam Strzelczyk, Arnfin Bergmann, Valeria Biermann et al. · Epilepsy & Behavior · 2016 · 27 citations

Medicine, Neurology, Clinical Neuroscience +14

Sleep and Quality of Life Under Prolonged Release Oxycodone/Naloxone for Severe Restless Legs Syndrome: An Analysis of Secondary Efficacy Variables of a Double-Blind, Randomized, Placebo-Controlled Study with an Open-Label Extension

Wolfgang H. Oertel, Yngve Hallström, G. Saletu‐Zyhlarz et al. · CNS Drugs · 2016 · 23 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15